GLP-1 Weight Loss Drugs and Knee Arthritis: What the Research Shows

Key Takeaways

• The STEP-9 trial (published in NEJM, October 2024) found that semaglutide reduced knee arthritis pain by 59% from baseline vs. 39% with placebo — a clinically significant difference
• The primary mechanism is weight loss — losing 7–10% of body weight measurably reduces joint load and pain
• Semaglutide also shows direct anti-inflammatory effects on joint tissue, independent of weight loss alone
• A 2024 Mass General Brigham analysis found GLP-1 drugs are cost-effective for patients with both obesity and knee OA
• GLP-1 drugs are not a replacement for proven treatments like hyaluronic acid injections or physical therapy — they’re potentially complementary tools
• Key limitation: These drugs are expensive, not covered by Medicare for weight loss, and only appropriate for patients with obesity (BMI ≥30) — not all knee arthritis patients qualify

---

A class of medications originally developed for type 2 diabetes is generating significant excitement in the osteoarthritis community. GLP-1 receptor agonists — the category that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are best known for dramatic weight loss results. But new clinical trial data shows they may directly reduce knee arthritis pain beyond what weight loss alone would explain.

Here’s what the research actually shows — including what it means for the 32 million Americans living with knee osteoarthritis.

---

What Are GLP-1 Drugs?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a natural gut hormone. They were originally developed to help people with type 2 diabetes control blood sugar, but their dramatic weight loss effects led to FDA approval for chronic weight management.

---

Why Weight Loss and Knee Arthritis Are Deeply Connected

Before discussing GLP-1 drugs specifically, it’s worth understanding the weight-joint pain connection.

Each pound of body weight creates approximately 3–4 pounds of force on the knee joint during walking — and up to 10 times body weight during activities like climbing stairs. This means:

• A person weighing 200 lbs generates 600–800 lbs of force on their knees with each step
• Losing just 10 lbs reduces knee joint force by 30–40 lbs per step
• Studies consistently show that losing 7–10% of body weight produces clinically meaningful reduction in knee arthritis pain and function

This mechanical reality is why weight management is a first-line recommendation for knee osteoarthritis in virtually every clinical guideline.

We’ve covered the weight-joint pain research in detail: Does Body Weight Really Affect Joint Pain? What Research Shows

---

The STEP-9 Trial: Semaglutide and Knee OA

The most compelling evidence comes from the STEP-9 trial (NCT05064735), a phase 3 randomized controlled trial published in The New England Journal of Medicine in October 2024.

What These Numbers Mean in Practice

A 14.1-point difference on the WOMAC pain scale (which runs 0–100) is clinically meaningful — it’s approximately the same improvement patients report after hyaluronic acid injections in large clinical trials. Patients starting with severe pain (scores of 70+) who achieved this improvement typically moved from difficulty walking even short distances to being able to climb stairs and walk 30+ minutes comfortably.

An Important Finding: Beyond Weight Loss

One of the most intriguing aspects of STEP-9 is that semaglutide’s pain benefits exceeded what weight loss alone would predict. Even accounting for weight differences between groups, the semaglutide group achieved greater pain reduction.

This suggests potential direct anti-inflammatory mechanisms in joint tissue — something that GLP-1 receptor research in laboratory studies supports, showing GLP-1 receptors on chondrocytes (cartilage cells) and the ability to reduce inflammatory markers like IL-6 and TNF-alpha in joint tissue.

However, it’s important to be appropriately cautious: this is one trial with a specific population, and more research is needed.

---

Mass General Brigham Cost-Effectiveness Analysis

A 2024 cost-effectiveness analysis from researchers at Mass General Brigham, published in Annals of Internal Medicine, evaluated GLP-1 drugs for patients with both obesity and knee osteoarthritis.

Key findings:

---

Real-World Evidence and Observational Data

Beyond controlled trials, observational data adds supportive evidence:

A study of patients in Shanghai using GLP-1 drugs (liraglutide or semaglutide) found that compared to matched controls:

• GLP-1 users achieved greater weight loss
• Had lower rates of knee surgery
• Showed slower cartilage loss on MRI imaging

While observational studies can’t prove causation, the consistency with STEP-9 trial data is encouraging.

---

What GLP-1 Drugs Are NOT

---

GLP-1 Drugs Alongside Traditional Joint Treatments

For patients who qualify and can access GLP-1 medications, the emerging picture is one of complementary use alongside traditional knee OA treatments:

Research suggests that weight loss achieved through GLP-1 drugs may actually improve outcomes from joint injections — less weight means less mechanical stress during the healing period and potentially better long-term injection efficacy.

---

Who Should Talk to Their Doctor About GLP-1 and Knee Pain?

This conversation makes most sense for patients who:

---

Frequently Asked Questions

Can Ozempic help with knee pain?

Early clinical evidence is promising. The STEP-9 trial published in NEJM (October 2024) found semaglutide (Wegovy/Ozempic’s active ingredient) reduced knee arthritis pain by 59% from baseline, significantly more than placebo. However, Ozempic/semaglutide is not FDA-approved for knee arthritis and was only studied in people with obesity — not all knee pain patients.

Will losing weight with GLP-1 drugs help my knee arthritis?

Yes — the weight loss mechanism is well-established. Every 10 lbs of body weight reduces knee joint force by approximately 30–40 lbs per step. Research consistently shows that losing 7–10% of body weight produces meaningful reduction in knee OA pain. GLP-1 drugs typically produce 10–15% weight loss, which falls into this therapeutic range.

Does Medicare cover GLP-1 drugs for knee pain?

No. Medicare currently does not cover GLP-1 receptor agonists for weight management. Coverage is limited to their FDA-approved use in type 2 diabetes management (e.g., Ozempic for diabetes). If you have a Medicare plan and qualify for GLP-1 treatment due to type 2 diabetes, coverage may apply — but not for the weight loss or arthritis indication specifically.

What about Ozempic for knee pain specifically — is it FDA approved?

No. As of 2026, no GLP-1 drug has FDA approval specifically for knee osteoarthritis. The STEP-9 trial data is compelling but represents phase 3 trial evidence, not approved indication. Prescribing GLP-1 drugs for knee pain specifically would be off-label use.

How long would it take to see knee pain improvement from a GLP-1 drug?

Based on STEP-9 data, significant weight loss and pain improvement occurred over the 68-week (approximately 16-month) study period, with progressive improvement throughout. This is a much longer treatment timeline than injections, which typically provide relief within weeks to months.

Are there any proven treatments for knee OA I should consider now?

Yes. While GLP-1 research is exciting, proven treatments with long track records include: hyaluronic acid (gel) injections (FDA-approved since 1997, Medicare covered), physical therapy, and cortisone injections for acute flares. These should be your foundation of care while the GLP-1 research continues to develop.

---

---

Related Resources

• Does Body Weight Really Affect Joint Pain? What Research Shows
• Hyaluronic Acid Injections: Complete Treatment Guide
• What Are the 3 Injections for Knee Pain?
• Knee Osteoarthritis: Complete Patient Guide
• Physical Therapy for Knee Arthritis: Evidence and Expectations
• Regenerative Medicine and Joint Pain: 2025 Research Update

---

References

1. Henriksen M, et al. “Effect of Liraglutide on Body Weight and Pain in Patients with Overweight and Knee Osteoarthritis.” New England Journal of Medicine, October 2024.

2. Kolasinski SL, et al. “2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.” Arthritis & Rheumatology, 2020.

3. Mass General Brigham Research Team. “Cost-Effectiveness of GLP-1 Receptor Agonists for Knee Osteoarthritis and Obesity.” Annals of Internal Medicine, 2024.

4. STEP-9 Clinical Trial (NCT05064735). ClinicalTrials.gov.

5. Zheng J, et al. “GLP-1 Receptor Agonists and Knee Osteoarthritis Outcomes: A Cohort Study.” Observational data from Shanghai cohort, 2024.

---

Last reviewed: March 2026

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs with significant side effect profiles and are not approved for the treatment of osteoarthritis. Consult your physician before starting, stopping, or changing any medication.